Ibopamine is a dopaminergic agonist recently shown to reduce renal arterial resistance and increase myocardial contractility and diuresis, without affecting heart rate or blood pressure in healthy volunteers, in patients with congestive heart failure, or in animals [1–5]. In patients with congestive heart failure, ibopamine significantly increased cardiac index and stroke work index, and decreased pulmonary pressure and pulmonary and peripheral vascular resistance without affecting heart rate or blood pressure. These effects were observed also in elderly patients. For example, in a 79-year-old patient with ischemic cardiomyopathy and chronic congestive heart failure (functional class 3), ibopamine increased cardiac index from 2.99 to 4.07 L/min·m2 (36%) and decreased systemic vascular resistance from 1748 to 1237 dyn·sec·cm-5 (29%) and pulmonary capillary wedge pressure from 17 to 14 mmHg (18%). In a 73-year-old patient with ischemic cardiomyopathy and congestive heart failure (functional class 4), ibopamine increased cardiac index from 2.85 to 5.04 L/min·m2 (77%) and decreased systemic vascular resistance from 1736 to 891 dyn·sec·cm-5. Pulmonary capillary wedge pressure was not significantly altered .
KeywordsDopamine Cardiomyopathy Cardiol Captopril Ibopamine
- 4.Mengeot PH, et al: Double-blind hemodynamic study of a new dopamine derivative (diisobutyric ester of N-methyl-dopamine) orally active in chronic congestive heart failure. G Ital Cardiol 40:900, 1977.Google Scholar
- 6.Marchionni N, et al: Ibopamine in congestive heart failure refractory in digitalis, diuretics and Captopril. Clin Pharmacol (in press).Google Scholar